Molecular functions of thyroid hormones and their clinical significance in liver-related diseases

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Chi, Hsiang Cheng ^a   Chen, Cheng Yi ^a   Tsai, Ming Ming ^b   Tsai, Chung Ying ^a   Lin, Kwang Huei ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA CATENIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPROTIROME; ESTROGEN RECEPTOR ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MB 07811; MB07811; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PRODRUG; PROTEIN KINASE C ALPHA; STAT3 PROTEIN; THYROID HORMONE; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ALCOHOLIC FATTY LIVER; ARTICLE; BINDING AFFINITY; CELL FUNCTION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FATTY LIVER; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HORMONE ACTION; HUMAN; LIVER CANCER; LIVER DISEASE; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROMOTER REGION; PROTEIN STRUCTURE; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; LIPID METABOLISM; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; LIVER DISEASES;

ANIMALS; HUMANS; LIPID METABOLISM; LIVER DISEASES; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; THYROID HORMONES;

EID: 84880098753     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/601361     Document Type: Article

References (180)

1. Huang Y.-H., Tsai M.-M., Lin K.-H., Thyroid hormone dependent regulation of target genes and their physiological significance. Chang Gung Medical Journal 2008 31 4 325 334 2-s2.0-48749096298
2. Pilo A., Iervasi G., Vitek F., Ferdeghini M., Cazzuola F., Bianchi R., Thyroidal and peripheral production of 3,5,3'-triiodothyronine in humans by multicompartmental analysis. American Journal of Physiology 1990 258 4, part 1 E715 E726 2-s2.0-0025366287
3. Tatar E., Kircelli F., Asci G., Carrero J. J., Gungor O., Demirci M. S., Ozbek S. S., Ceylan N., Ozkahya M., Toz H., Ok E., Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clinical Journal of the American Society of Nephrology 2011 6 9 2240 2246 2-s2.0-80052605638 10.2215/CJN.02540311
4. Tatar E., Sezis Demirci M., Kircelli F., Gungor O., Yaprak M., Asci G., Basci A., Ozkahya M., Ok E., The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. International Urology and Nephrology 2011 44 2 601 606 2-s2.0-79960440930 10.1007/s11255-011-0034-7
5. Feely J., Isles T. E., Screening for thyroid dysfunction in diabetics. British Medical Journal 1979 1 6179 1678 2-s2.0-0018384101
6. Gray R. S., Irvine W. J., Clarke B. F., Screening for thyroid dysfunction in diabetics. British medical journal 1979 2 6202 1439 2-s2.0-0018591292
7. 3 ratio as prognostic indices. Gastroenterologia Japonica 1987 22 3 344 353 2-s2.0-0023274102
8. Borzio M., Caldara R., Borzio F., Thyroid function tests in chronic liver disease: evidence for multiple abnormalities despite clinical euthyroidism. Gut 1983 24 7 631 636 2-s2.0-0020535730
9. Carulli L., Ballestri S., Lonardo A., Lami F., Violi E., Losi L., Bonilauri L., Verrone A. M., Odoardi M. R., Scaglioni F., Bertolotti M., Loria P., Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Internal and Emergency Medicine 2011 8 4 297 305 2-s2.0-79955685997 10.1007/s11739-011-0609-4
10. Chamba A., Neuberger J., Strain A., Hopkins J., Sheppard M. C., Franklyn J. A., Expression and function of thyroid hormone receptor variants in normal and chronically diseased human liver. Journal of Clinical Endocrinology and Metabolism 1996 81 1 360 367 2-s2.0-0030068622 10.1210/jc.81.1.360
11. Liangpunsakul S., Chalasani N., Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? Journal of Clinical Gastroenterology 2003 37 4 340 343 2-s2.0-0141790139 10.1097/00004836-200310000-00014
12. 3) and TR β agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. The FASEB Journal 2008 22 8 2981 2989 2-s2.0-48749083328 10.1096/fj.08-108464
13. Cable E. E., Finn P. D., Stebbins J. W., Hou J., Ito B. R., van Poelje P. D., Linemeyer D. L., Erion M. D., Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009 49 2 407 417 2-s2.0-61949147670 10.1002/hep.22572
14. Akino K., Akita S., Mizuguchi T., Takumi I., Yu R., Wang X.-Y., Rozga J., Demetriou A. A., Melmed S., Ohtsuru A., Yamashita S., A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. Journal of Surgical Research 2005 129 1 142 146 2-s2.0-27144538594 10.1016/j.jss.2005.04.019
15. Mollica M. P., Lionetti L., Moreno M., Lombardi A., De Lange P., Antonelli A., Lanni A., Cavaliere G., Barletta A., Goglia F., 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. Journal of Hepatology 2009 51 2 363 370 2-s2.0-67649236153 10.1016/j.jhep.2009.03.023
16. Naehrlich L., Dorr H. G., Bagheri-Behrouzi A., Rauh M., Iodine deficiency and subclinical hypothyroidism are common in cystic fibrosis patients. Journal of Trace Elements in Medicine and Biology 2013 27 2 122 125
17. 3 level in hepatitis B and C related cirrhosis by severity of liver damage. Annals of Hepatology 2012 11 5 667 671
18. Itoh S., Matsuo S., Oda T., Marutani K., Sasaki K., Triiodothyronine level and triiodothyronine/thyroxine ratio in HB(e)Ag-positive chronic hepatitis patients treated with prednisolone withdrawal. Digestive Diseases and Sciences 1990 35 9 1110 1114 2-s2.0-0025180795 10.1007/BF01537583
19. Barlow C., Meister B., Lardelli M., Lendahl U., Vennström B., Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO Journal 1994 13 18 4241 4250 2-s2.0-0028133444
20. Sap J., Munoz A., Damm K., The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986 324 6098 635 640 2-s2.0-0023025178
21. Lin K. H., Shieh H. Y., Chen S. L., Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Molecular Carcinogenesis 1999 26 1 53 61
22. Chan I. H., Privalsky M. L., Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene 2006 25 25 3576 3588 2-s2.0-33745118310 10.1038/sj.onc.1209389
23. Chan I. H., Privalsky M. L., Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire. Oncogene 2009 28 47 4162 4174 2-s2.0-70949101412 10.1038/onc.2009.265
24. Chen R.-N., Huang Y.-H., Yeh C.-T., Liao C.-H., Lin K.-H., Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Research 2008 68 6 1697 1706 2-s2.0-40949153571 10.1158/0008-5472.CAN-07-5492
25. Chi H. C., Chen S. L., Liao C. J., Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL. Cell Death & Differentiation 2012 19 11 1802 1814
26. Liao C.-S., Tai P.-J., Huang Y.-H., Chen R.-N., Wu S.-M., Kuo L.-W., Yeh C.-T., Tsai M.-M., Chen W.-J., Lin K.-H., Regulation of AKR1B1 by thyroid hormone and its receptors. Molecular and Cellular Endocrinology 2009 307 1-2 109 117 2-s2.0-67349236706 10.1016/j.mce.2009.04.013
27. Liao C.-H., Yeh C.-T., Huang Y.-H., Wu S.-M., Chi H.-C., Tsai M.-M., Tsai C.-Y., Liao C.-J., Tseng Y.-H., Lin Y.-H., Chen C.-Y., Chung I.-H., Cheng W.-L., Chen W.-J., Lin K.-H., Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology 2012 55 3 910 920 2-s2.0-84857443182 10.1002/hep.24740
28. Martínez-Iglesias O., Garcia-Silva S., Tenbaum S. P., Regadera J., Larcher F., Paramio J. M., Vennström B., Aranda A., Thyroid hormone receptor β 1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Research 2009 69 2 501 509 2-s2.0-58349109708 10.1158/0008-5472.CAN-08-2198
29. Brenta G., Danzi S., Klein I., Potential therapeutic applications of thyroid hormone analogs. Nature Clinical Practice Endocrinology and Metabolism 2007 3 9 632 640 2-s2.0-34548086807 10.1038/ncpendmet0590
30. Edelman I. S., Thyroid thermogenesis. New England Journal of Medicine 1974 290 23 1303 1308 2-s2.0-0016385846
31. Oppenheimer J. H., Schwartz H. L., Lane J. T., Thompson M. P., Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. Journal of Clinical Investigation 1991 87 1 125 132 2-s2.0-0025970029
32. Klein I., Ojamaa K., Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 7 501 509 2-s2.0-0035864975 10.1056/NEJM200102153440707
33. Dayan C. M., Panicker V., Novel insights into thyroid hormones from the study of common genetic variation. Nature Reviews Endocrinology 2009 5 4 211 218 2-s2.0-67649373281 10.1038/nrendo.2009.19
34. Weinberger C., Thompson C. C., Ong E. S., The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986 324 6098 641 646 2-s2.0-0022998995
35. Cheng S.-Y., Leonard J. L., Davis P. J., Molecular aspects of thyroid hormone actions. Endocrine Reviews 2010 31 2 139 170 2-s2.0-77953639982 10.1210/er.2009-0007
36. Cheng S.-Y., Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Reviews in Endocrine and Metabolic Disorders 2000 1 1-2 9 18 2-s2.0-0033756564
37. Williams G. R., Cloning and characterization of two novel thyroid hormone receptor β isoforms. Molecular and Cellular Biology 2000 20 22 8329 8342 2-s2.0-0033762445 10.1128/MCB.20.22.8329-8342.2000
38. Mitsuhashi T., Tennyson G. E., Nikodem V. M., Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormone. Proceedings of the National Academy of Sciences of the United States of America 1988 85 16 5804 5808 2-s2.0-0006850898
39. Matsushita A., Misawa H., Andoh S., Natsume H., Nishiyama K., Sasaki S., Nakamura H., Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT. Journal of Endocrinology 2000 167 3 493 503 2-s2.0-0034522171 10.1677/joe.0.1670493
40. Sakurai A., Nakai A., DeGroot L. J., Expression of three forms of thyroid hormone receptor in human tissues. Molecular Endocrinology 1989 3 2 392 399 2-s2.0-0024600707
41. Ying H., Suzuki H., Zhao L., Willingham M. C., Meltzer P., Cheng S.-Y., Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis. Cancer Research 2003 63 17 5274 5280 2-s2.0-0141705447
42. Jones I., Ng L., Liu H., Forrest D., An intron control region differentially regulates expression of thyroid hormone receptor β 2 in the cochlea, pituitary, and cone photoreceptors. Molecular Endocrinology 2007 21 5 1108 1119 2-s2.0-34250896056 10.1210/me.2007-0037
43. Tagami T., Yamamoto H., Moriyama K., Sawai K., Usui T., Shimatsu A., Naruse M., Identification of a novel human thyroid hormone receptor β isoform as a transcriptional modulator. Biochemical and Biophysical Research Communications 2010 396 4 983 988 2-s2.0-77953290421 10.1016/j.bbrc.2010.05.038
44. 3). Endocrine Research Communications 1975 2 4-5 309 325 2-s2.0-0016725404
45. Yen P. M., Physiological and molecular basis of Thyroid hormone action. Physiological Reviews 2001 81 3 1097 1142 2-s2.0-0034964207
46. Aranda A., Pascual A., Nuclear hormone receptors and gene expression. Physiological Reviews 2001 81 3 1269 1304 2-s2.0-0034957480
47. Larsen P. R., Thyroid hormone analogs and metabolites: new applications for an old hormone? Nature Clinical Practice Endocrinology and Metabolism 2009 5 1 1 2-s2.0-57649231483 10.1038/ncpendmet1025
48. Pascual A., Aranda A., Thyroid hormone receptors, cell growth and differentiation. Biochimica et Biophysica Acta 2013 1830 3908 3916 2-s2.0-84859643291 10.1016/j.bbagen.2012.03.012
49. Zhang X.-K., Pfahl M., Regulation of retinoid and thyroid hormone action through homodimeric and heterodimeric receptors. Trends in Endocrinology and Metabolism 1993 4 5 156 162 2-s2.0-0027225769 10.1016/1043-2760(93)90105-N
50. Kliewer S. A., Umesono K., Mangelsdorf D. J., Evans R. M., Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992 355 6359 446 449 2-s2.0-0026592518 10.1038/355446a0
51. Perissi V., Staszewski L. M., McInerney E. M., Kurokawa R., Krones A., Rose D. W., Lambert M. H., Milburn M. V., Glass C. K., Rosenfeld M. G., Molecular determinants of nuclear receptor-corepressor interaction. Genes and Development 1999 13 24 3198 3208 2-s2.0-0033572656 10.1101/gad.13.24.3198
52. McKenna N. J., O'Malley B. W., Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002 108 4 465 474 2-s2.0-0037154974 10.1016/S0092-8674(02)00641-4
53. Fondell J. D., Ge H., Roeder R. G., Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proceedings of the National Academy of Sciences of the United States of America 1996 93 16 8329 8333 2-s2.0-0029758906 10.1073/pnas.93.16.8329
54. Lazar M. A., Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrine Reviews 1993 14 2 184 193 2-s2.0-0027416347 10.1210/er.14.2.184
55. Davis F. B., Tang H.-Y., Shih A., Keating T., Lansing L., Hercbergs A., Fenstermaker R. A., Mousa A., Mousa S. A., Davis P. J., Lin H.-Y., Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Research 2006 66 14 7270 7275 2-s2.0-33746897636 10.1158/0008-5472.CAN- 05-4365
56. Bergh J. J., Lin H.-Y., Lansing L., Mohamed S. N., Davis F. B., Mousa S., Davis P. J., Integrin α V β 3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005 146 7 2864 2871 2-s2.0-22144494707 10.1210/en.2005-0102
57. Bhargava M., Lei J., Ingbar D. H., Nongenomic actions of L-thyroxine and 3,5,3′-triiodo-L-thyronine. Focus on 'L-Thyroxine vs. 3,5,3′- triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase'. American Journal of Physiology 2009 296 5 C977 C979 2-s2.0-66149095036 10.1152/ajpcell.00116.2009
58. Lin H.-Y., Sun M., Tang H.-Y., Lin C., Luidens M. K., Mousa S. A., Incerpi S., Drusano G. L., Davis F. B., Davis P. J., L-thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. American Journal of Physiology 2009 296 5 C980 C991 2-s2.0-66149090297 10.1152/ajpcell.00305.2008
59. Davis P. J., Shih A., Lin H.-Y., Martino L. J., Davis F. B., Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. Journal of Biological Chemistry 2000 275 48 38032 38039 2-s2.0-0034532451 10.1074/jbc.M002560200
60. Cao H. J., Lin H.-Y., Luidens M. K., Davis F. B., Davis P. J., Cytoplasm-to-nucleus shuttling of thyroid hormone receptor- β 1 (TR β 1) is directed from a plasma membrane integrin receptor by thyroid hormone. Endocrine Research 2009 34 1-2 31 42 2-s2.0-67650899238 10.1080/ 07435800902911810
61. Tang H.-Y., Lin H.-Y., Zhang S., Davis F. B., Davis P. J., Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004 145 7 3265 3272 2-s2.0-3042693890 10.1210/en.2004-0308
62. Baumann C. T., Maruvada P., Hager G. L., Yen P. M., Nuclear Cytoplasmic Shuttling by Thyroid Hormone Receptors: multiple protein interactions are required for nuclear retention. Journal of Biological Chemistry 2001 276 14 11237 11245 2-s2.0-0035815621 10.1074/jbc.M011112200
63. Lin H.-Y., Shih A., Davis F. B., Davis P. J., Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochemical Journal 1999 338 2 427 432 2-s2.0-0033105655 10.1042/0264-6021:3380427
64. 3-dependent phosphorylation and translocation of Trip230 from the Golgi complex to the nucleus. Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4443 4448 2-s2.0-0033551146 10.1073/pnas.96.8.4443
65. Vasudevan N., Ogawa S., Pfaff D., Estrogen and thyroid hormone receptor interactions: physiological flexibility by molecular specificity. Physiological Reviews 2002 82 4 923 944 2-s2.0-0036788123
66. Moeller L. C., Cao X., Dumitrescu A. M., Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nuclear Receptor Signaling 2006 4 e020
67. Cao X., Kambe F., Moeller L. C., Refetoff S., Seo H., Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Molecular Endocrinology 2005 19 1 102 112 2-s2.0-11244346968 10.1210/me.2004-0093
68. Moeller L. C., Dumitrescu A. M., Refetoff S., Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1 α and glycolytic genes. Molecular Endocrinology 2005 19 12 2955 2963 2-s2.0-28144463727 10.1210/me.2004-0542
69. Fulton D., Gratton J.-P., McCabe T. J., Fontana J., Fujio Y., Walsh K., Franke T. F., Papapetropoulos A., Sessa W. C., Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999 399 6736 597 601 2-s2.0-0033584337
70. Hiroi Y., Kim H. H., Ying H., Rapid nongenomic actions of thyroid hormone. Proceedings of the National Academy of Sciences of the United States of America 2006 103 38 14104 14109
71. Storey N. M., Gentile S., Ullah H., Russo A., Muessel M., Erxleben C., Armstrong D. L., Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone. Proceedings of the National Academy of Sciences of the United States of America 2006 103 13 5197 5201 2-s2.0-33645514600 10.1073/pnas.0600089103
72. Lei J., Nowbar S., Mariash C. N., Ingbar D. H., Thyroid hormone stimulates Na-K-ATPase activity and its plasma membrane insertion in rat alveolar epithelial cells. American Journal of Physiology 2003 285 3 L762 L772 2-s2.0-0041508705
73. 3 increases Na-K-ATPase activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells. American Journal of Physiology 2008 294 4 L749 L754 2-s2.0-42049095481 10.1152/ajplung.00335.2007
74. Brundtland G. H., From the World Health Organization. Reducing risks to health, promoting healthy life. Journal of the American Medical Association 2002 288 16 1974 2-s2.0-0037163917
75. Bode J. C., Mexas P., Martini G. A., Kruse G., Alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis. Drinking behavior and incidence of clinical, clinico-chemical and histological findings in 282 patients. Deutsche Medizinische Wochenschrift 1984 109 40 1516 1521 2-s2.0-0021228608
76. Joos W., Mörl M., Alcohol-induced organic lesions. 3. Liver damage-alcoholic fatty liver, alcoholic hepatitis, acute and chronic clinical course. Fortschritte der Medizin 1984 102 4 79 82 2-s2.0-0021771082
77. Ozsoy S., Esel E., Izgi H. B., Sofuoglu S., Thyroid function in early and late alcohol withdrawal: relationship with aggression, family history, and onset age of alcoholism. Alcohol and Alcoholism 2006 41 5 515 521 2-s2.0-33748799672 10.1093/alcalc/agl056
78. Hegedus L., Decreased thyroid gland volume in alcoholic cirrhosis of the liver. Journal of Clinical Endocrinology and Metabolism 1984 58 5 930 933 2-s2.0-0021273318
79. Hepner G. W., Chopra I. J., Serum thyroid hormone levels in patients with liver disease. Archives of Internal Medicine 1979 139 10 1117 1120 2-s2.0-0018597018 10.1001/archinte.139.10.1117
80. Walfish P. G., Orrego H., Israel Y., Serum triiodothyronine and other clinical and laboratory indices of alcoholic liver disease. Annals of Internal Medicine 1979 91 1 13 16 2-s2.0-0018388472
81. Isreal Y., Walfish P. G., Orrego H., Thyroid hormones in alcoholic liver disease. Effect of treatment with 6-n-propylthiouracil. Gastroenterology 1979 76 1 116 122 2-s2.0-0018341773
82. Burra P., Franklyn J. A., Ramsden D. B., Elias E., Sheppard M. C., Severity of alcoholic liver disease and markers of thyroid and steroid status. Postgraduate Medical Journal 1992 68 804 804 810 2-s2.0-0026697782
83. Loosen P. T., Wilson I. C., Dew B. W., Tipermas A., Thyrotropin-releasing hormone (TRH) in abstinent alcoholic men. American Journal of Psychiatry 1983 140 9 1145 1149 2-s2.0-0020627172
84. Das K., Kar P., Non-alcoholic steatohepatitis. Journal of Association of Physicians of India 2005 53 195 199 2-s2.0-20144364416
85. Ota T., Takamura T., Kurita S., Matsuzawa N., Kita Y., Uno M., Akahori H., Misu H., Sakurai M., Zen Y., Nakanuma Y., Kaneko S., Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007 132 1 282 293 2-s2.0-33846253661 10.1053/j.gastro.2006.10. 014
86. Adams L. A., Angulo P., Recent concepts in non-alcoholic fatty liver disease. Diabetic Medicine 2005 22 9 1129 1133 2-s2.0-24044536090 10.1111/j.1464-5491.2005.01748.x
87. Adams L. A., Angulo P., Lindor K. D., Nonalcoholic fatty liver disease. Canadian Medical Association Journal 2005 172 7 899 905 2-s2.0-17444417085 10.1503/cmaj.045232
88. Buckley G. F., Hartroft W. S., Pathology of choline deficiency in the mouse; observations with special reference to liver. A. M. A. Achives of Pathology 1955 59 2 185 197 2-s2.0-0000061502
89. Newberne P. M., Lipotropic factors and oncogenesis. Advances in Experimental Medicine and Biology 1986 206 223 251 2-s2.0-0022831430
90. Zeisel S. H., Choline deficiency. Journal of Nutritional Biochemistry 1990 1 7 332 349 2-s2.0-0025151131 10.1016/0955-2863(90)90001-2
91. Grover G. J., Egan D. M., Sleph P. G., Beehler B. C., Chiellini G., Nguyen N.-H., Baxter J. D., Scanlan T. S., Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine. Endocrinology 2004 145 4 1656 1661 2-s2.0-1642505721 10.1210/en.2003-0973
92. Trost S. U., Swanson E., Gloss B., Wang-Iverson D. B., Zhang H., Volodarsky T., Grover G. J., Baxter J. D., Chiellini G., Scanlan T. S., Dillmann W. H., The thyroid hormone receptor- β -selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000 141 9 3057 3064 2-s2.0-17744387900 10.1210/en.141.9.3057
93. Johansson L., Rudling M., Scanlan T. S., Lundåsen T., Webb P., Baxter J., Angelin B., Parini P., Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proceedings of the National Academy of Sciences of the United States of America 2005 102 29 10297 10302 2-s2.0-22644432001 10.1073/pnas.0504379102
94. Erion M. D., Cable E. E., Ito B. R., Jiang H., Fujitaki J. M., Finn P. D., Zhang B.-H., Hou J., Boyer S. H., Van Poelje P. D., Linemeyer D. L., Targeting thyroid hormone receptor- β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proceedings of the National Academy of Sciences of the United States of America 2007 104 39 15490 15495 2-s2.0-34848827936 10.1073/pnas.0702759104
95. Grasselli E., Voci A., Demori I., Canesi L., De Matteis R., Goglia F., Lanni A., Gallo G., Vergani L., 3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver. Journal of Endocrinology 2012 212 2 149 158 2-s2.0-84856775058 10.1530/JOE-11-0288
96. Castillo M., Hall J. A., Correa-Medina M., Ueta C., Kang H. W., Cohen D. E., Bianco A. C., Disruption of thyroid hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and liver steatosis only at thermoneutrality. Diabetes 2011 60 4 1082 1089 2-s2.0-79953225879 10.2337/db10-0758
97. Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D.-S., Mehrbod F., Jaskunas S. R., Shanafelt A. B., FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005 115 6 1627 1635 2-s2.0-20444435873 10.1172/JCI23606
98. Adams A. C., Astapova I., Fisher F. M., Badman M. K., Kurgansky K. E., Flier J. S., Hollenberg A. N., Maratos-Flier E., Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPAR α -dependent manner. Journal of Biological Chemistry 2010 285 19 14078 14082 2-s2.0-77951995518 10.1074/jbc.C110.107375
99. Chung G. E., Kim D., Kim W., Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. Journal of Hepatology 2012 57 1 150 156
100. Ittermann T., Haring R., Wallaschofski H., Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid 2012 22 6 568 574
101. Zhang J., Sun H., Chen L., Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects. Journal of Huazhong University of Science and Technology 2012 32 1 47 52
102. Fang S., Suh J. M., Atkins A. R., Hong S.-H., Leblanc M., Nofsinger R. R., Yu R. T., Downes M., Evans R. M., Corepressor SMRT promotes oxidative phosphorylation in adipose tissue and protects against diet-induced obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2011 108 8 3412 3417 2-s2.0-79952775519 10.1073/pnas.1017707108
103. Song Y., Shan S., Zhang Y., Liu W., Ding W., Ren W., Xia H., Li X., Zhang Q., Zhao L., Li X., Yan J., Ying H., Ligand-dependent corepressor acts as a novel corepressor of thyroid hormone receptor and represses hepatic lipogenesis in mice. Journal of Hepatology 2012 56 1 248 254 2-s2.0-83555172601 10.1016/j.jhep.2011.07.014
104. Sinha R. A., You S. H., Zhou J., Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. Journal of Clinical Investigation 2012 122 7 2428 2438
105. Pelletier P., Gauthier K., Sideleva O., Samarut J., Silva J. E., Mice lacking the thyroid hormone receptor- α gene spend more energy in thermogenesis, burn more fat, and are less sensitive to high-fat diet-induced obesity. Endocrinology 2008 149 12 6471 6486 2-s2.0-57349178401 10.1210/en.2008-0718
106. Sjögren M., Alkemade A., Mittag J., Nordström K., Katz A., Rozell B., Westerblad H., Arner A., Vennström B., Hypermetabolism in mice caused by the central action of an unliganded thyroid hormone receptor α 1. EMBO Journal 2007 26 21 4535 4545 2-s2.0-35648985719 10.1038/sj.emboj.7601882
107. Jornayvaz F. R., Lee H.-Y., Jurczak M. J., Alves T. C., Guebre-Egziabher F., Guigni B. A., Zhang D., Samuel V. T., Silva J. E., Shulman G. I., Thyroid hormone receptor- α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 2012 153 2 583 591 2-s2.0-84856097557 10.1210/en.2011-1793
108. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
109. Tsochatzis E. A., Meyer T., Burroughs A. K., Hepatocellular carcinoma. New England Journal of Medicine 2012 366 1 92 2-s2.0-84856158123 10.1056/NEJMc1112501
110. Fattovich G., Stroffolini T., Zagni I., Donato F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 5, supplement 1 S35 S50 2-s2.0-7044272630 10.1053/j.gastro.2004.09.014
111. El-Serag H. B., Rudolph K. L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 7 2557 2576 2-s2.0-34250020201 10.1053/j.gastro.2007.04.061
112. Chen C.-J., Yang H.-I., Iloeje U. H., Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009 49 5, supplement S72 S84 2-s2.0-66149187115 10.1002/hep.22884
113. Davis G. L., Alter M. J., El-Serag H., Poynard T., Jennings L. W., Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010 138 2 513 521 2-s2.0-75149163334 10.1053/j.gastro.2009.09.067
114. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. New England Journal of Medicine 2003 348 17 1625 1638 2-s2.0-0037464510 10.1056/NEJMoa021423
115. Sorvillo F., Mazziotti G., Carbone A., Morisco F., Cioffi M., Rotondi M., Stornaiuolo G., Amato G., Gaeta G. B., Caporaso N., Carella C., Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. Clinical Endocrinology 2003 58 2 207 212 2-s2.0-0037318897 10.1046/j.1365-2265.2003.01697.x
116. González-Sancho J. M., García V., Bonilla F., Muñoz A., Thyroid hormone receptors/THR genes in human cancer. Cancer Letters 2003 192 2 121 132 2-s2.0-0345700241 10.1016/S0304-3835(02)00614-6
117. Lin K.-H., Zhu X.-G., Shieh H.-Y., Hsu H.-C., Chen S.-T., McPhie P., Cheng S.-Y., Identification of naturally occurring dominant negative mutants of thyroid hormone α 1 and β 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 1996 137 10 4073 4081 2-s2.0-0029741543 10.1210/en.137.10.4073
118. Lin K.-H., Wu Y.-H., Chen S.-L., Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators. Endocrinology 2001 142 2 653 662 2-s2.0-0035106358 10.1210/en.142.2.653
119. Ledda-Columbano G. M., Perra A., Concas D., Cossu C., Molotzu F., Sartori C., Shinozuka H., Columbano A., Different effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma. Toxicologic Pathology 2003 31 1 113 120 2-s2.0-0037261428 10.1080/01926230309731
120. Perra A., Kowalik M. A., Pibiri M., Ledda-Columbano G. M., Columbano A., Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology 2009 49 4 1287 1296 2-s2.0-65449134288 10.1002/hep.22750
121. Ledda-Columbano G. M., Perra A., Piga R., Pibiri M., Loi R., Shinozuka H., Columbano A., Cell proliferation induced by 3,3',5-triiodo-L-thyronine is associated with a reduction in the number of preneoplastic hepatic lesions. Carcinogenesis 1999 20 12 2299 2304 2-s2.0-0033390730
122. Ledda-Columbano G. M., Perra A., Loi R., Shinozuka H., Columbano A., Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Research 2000 60 3 603 609 2-s2.0-0033960561
123. Hassan M. M., Kaseb A., Li D., Patt Y. Z., Vaunthey J.-N., Thomas M. B., Curley S. A., Spitz M. R., Sherman S. I., Abdalla E. K., Davilla M., Lozano R. D., Hassan D. M., Chan W., Brown T. D., Abbruzzese J. L., Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009 49 5 1563 1570 2-s2.0-66149088423 10.1002/hep.22793
124. Chen R.-N., Huang Y.-H., Lin Y.-C., Yeh C.-T., Liang Y., Chen S.-L., Lin K.-H., Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology 2008 149 8 3817 3831 2-s2.0-47949130373 10.1210/en.2007-0989
125. Yen C.-C., Huang Y.-H., Liao C.-Y., Liao C.-J., Cheng W.-L., Chen W.-J., Lin K.-H., Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. Journal of Molecular Endocrinology 2006 36 1 9 21 2-s2.0-33244486755 10.1677/jme.1.01911
126. De Caestecker M., The transforming growth factor- β superfamily of receptors. Cytokine and Growth Factor Reviews 2004 15 1 1 11 2-s2.0-1642473157 10.1016/j.cytogfr.2003.10.004
127. Thiery J. P., Sleeman J. P., Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006 7 2 131 142 2-s2.0-33244463813 10.1038/nrm1835
128. Coulouarn C., Factor V. M., Thorgeirsson S. S., Transforming growth factor- β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008 47 6 2059 2067 2-s2.0-46249085489 10.1002/hep.22283
129. Molloy S. S., Anderson E. D., Jean F., Thomas G., Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends in Cell Biology 1999 9 1 28 35 2-s2.0-0033059994 10.1016/S0962-8924(98)01382-8
130. Bassi D. E., Mahloogi H., Klein-Szanto A. J., The proprotein convertases
131. Foekens J. A., Schmitt M., Van Putten W. L. J., Peters H. A., Bontenbal M., Janicke F., Klijn J. G. M., Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Research 1992 52 21 6101 6105 2-s2.0-0026440080
132. Tang L., Han X., The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomedicine & Pharmacotherapy 2013 67 2 179 182
133. Chen G.-Y., Chi L.-M., Chi H.-C., Tsai M.-M., Tsai C.-Y., Tseng Y.-H., Lin Y.-H., Chen W.-J., Huang Y.-H., Lin K.-H., Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells. Molecular and Cellular Proteomics 2012 11 4 2-s2.0-84859807729 10.1074/mcp.M111.011270
134. Dass K., Ahmad A., Azmi A. S., Sarkar S. H., Sarkar F. H., Evolving role of uPA/uPAR system in human cancers. Cancer Treatment Reviews 2008 34 2 122 136 2-s2.0-40649121508 10.1016/j.ctrv.2007.10.005
135. Carmeliet P., Moons L., Dewerchin M., Rosenberg S., Herbert J.-M., Lupu F., Collen D., Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis vascular wound healing in mice. Journal of Cell Biology 1998 140 1 233 245 2-s2.0-0031893413 10.1083/jcb.140.1.233
136. Paschos K. A., Canovas D., Bird N. C., Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases. Hippokratia 2009 13 1 23 31 2-s2.0-65949122103
137. Blasi F., Sidenius N., The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. The FEBS Letters 2010 584 9 1923 1930 2-s2.0-77951883821 10.1016/j.febslet.2009.12.039
138. Laufs S., Schumacher J., Allgayer H., Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006 5 16 1760 1771 2-s2.0-33749072892
139. Yasuda S., Morokawa N., Wong G. W., Rossi A., Madhusudhan M. S., Šali A., Askew Y. S., Adachi R., Silverman G. A., Krilis S. A., Stevens R. L., Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase ε /PRSS22. Blood 2005 105 10 3893 3901 2-s2.0-20844432525 10.1182/blood-2003-10-3501
140. Wu S.-M., Huang Y.-H., Yeh C.-T., Tsai M.-M., Liao C.-H., Cheng W.-L., Chen W.-J., Lin K.-H., Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells. Oncogene 2011 30 17 2057 2069 2-s2.0-79955473609 10.1038/onc.2010.585
141. Berdowska I., Cysteine proteases as disease markers. Clinica Chimica Acta 2004 342 1-2 41 69 2-s2.0-1542604677 10.1016/j.cccn.2003.12.016
142. Joyce J. A., Hanahan D., Multiple roles for cysteine cathepsins in cancer. Cell Cycle 2004 3 12 1516 1519 2-s2.0-17144394796
143. Gocheva V., Joyce J. A., Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007 6 1 60 64 2-s2.0-33846643454
144. Palermo C., Joyce J. A., Cysteine cathepsin proteases as pharmacological targets in cancer. Trends in Pharmacological Sciences 2008 29 1 22 28 2-s2.0-37549070672 10.1016/j.tips.2007.10.011
145. Reya T., Clevers H., Wnt signalling in stem cells and cancer. Nature 2005 434 7035 843 850 2-s2.0-17244376814 10.1038/nature03319
146. Cui J., Zhou X., Liu Y., Tang Z., Romeih M., Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. Journal of Gastroenterology and Hepatology 2003 18 3 280 287 2-s2.0-0037367866 10.1046/j.1440-1746.2003.02973.x
147. Suzuki T., Yano H., Nakashima Y., Nakashima O., Kojiro M., β -Catenin expression in hepatocellular carcinoma: a possible participation of β -catenin in the dedifferentiation process. Journal of Gastroenterology and Hepatology 2002 17 9 994 1000 2-s2.0-0036379830 10.1046/j.1440-1746.2002. 02774.x
148. Inagawa S., Itabashi M., Adachi S., Kawamoto T., Hori M., Shimazaki J., Yoshimi F., Fukao K., Expression and prognostic roles of β -catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clinical Cancer Research 2002 8 2 450 456 2-s2.0-0036190930
149. Hsu H.-C., Jeng Y.-M., Mao T.-L., Chu J.-S., Lai P.-L., Peng S.-Y., β -catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. American Journal of Pathology 2000 157 3 763 770 2-s2.0-0034495080
150. Niehrs C., Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006 25 57 7469 7481 2-s2.0-33845359084 10.1038/sj.onc.1210054
151. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C.-P., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 6 673 682 2-s2.0-13344285339 10.1016/1074-7613(95)90057-8
152. Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A., Ashkenazi A., Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry 1996 271 22 12687 12690 2-s2.0-17544367410 10.1074/jbc.271.22.12687
153. Johnstone R. W., Frew A. J., Smyth M. J., The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews Cancer 2008 8 10 782 798 2-s2.0-52649109068 10.1038/nrc2465
154. Hetschko H., Voss V., Horn S., Seifert V., Prehn J. H. M., Kögel D., Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. Journal of Neuro-Oncology 2008 86 3 265 272 2-s2.0-38049073240 10.1007/s11060-007-9472-6
155. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Röder C., Kalthoff H., Wajant H., TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006 25 56 7434 7439 2-s2.0-33845221022 10.1038/sj.onc.1209719
156. Zender L., Hütker S., Mundt B., Waltemathe M., Klein C., Trautwein C., Malek N. P., Manns M. P., Kühnel F., Kubicka S., NF B-mediated upregulation of Bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. Hepatology 2005 41 2 280 288 2-s2.0-19944432895 10.1002/hep.20566
157. Cory S., Adams J. M., The BCL2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer 2002 2 9 647 656 2-s2.0-0036716281 10.1038/nrc883
158. Johnstone R. W., Ruefli A. A., Lowe S. W., Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002 108 2 153 164 2-s2.0-0037169358 10.1016/S0092-8674(02)00625-6
159. Vlotides G., Eigler T., Melmed S., Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews 2007 28 2 165 186 2-s2.0-34249668278 10.1210/er.2006-0042
160. Ying H., Furuya F., Zhao L., Araki O., West B. L., Hanover J. A., Willingham M. C., Cheng S.-Y., Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone β receptor inhibits mitotic progression. Journal of Clinical Investigation 2006 116 11 2972 2984 2-s2.0-33750592404 10.1172/JCI28598
161. Liao C.-H., Yeh S.-C., Huang Y.-H., Chen R.-N., Tsai M.-M., Chen W.-J., Chi H.-C., Tai P.-J., Liao C.-J., Wu S.-M., Cheng W.-L., Pai L.-M., Lin K.-H., Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocrine-Related Cancer 2010 17 1 99 111 2-s2.0-77449085159 10.1677/ERC-09-0050
162. Wu S.-M., Huang Y.-H., Lu Y.-H., Chien L.-F., Yeh C.-T., Tsai M.-M., Liao C.-H., Chen W.-J., Liao C.-J., Cheng W.-L., Lin K.-H., Thyroid hormone receptor-mediated regulation of the methionine adenosyltransferase 1 gene is associated with cell invasion in hepatoma cell lines. Cellular and Molecular Life Sciences 2010 67 11 1831 1843 2-s2.0-77952556356 10.1007/s00018-010-0281-2
163. Lefrançois-Martinez A.-M., Bertherat J., Val P., Tournaire C., Gallo-Payet N., Hyndman D., Veyssière G., Bertagna X., Jean C., Martinez A., Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 6 3010 3019 2-s2.0-2942668375 10.1210/jc.2003-031830
164. Qiu L., Wu X., Chau J. F. L., Szeto I. Y. Y., Wing Y. T., Guo Z., Chung S. K., Oates P. J., Chung S. S. M., Yang J. Y., Aldose reductase regulates hepatic peroxisome proliferator-activated receptor α phosphorylation and activity to impact lipid homeostasis. Journal of Biological Chemistry 2008 283 25 17175 17183 2-s2.0-47749155983 10.1074/jbc.M801791200
165. Mudd S. H., Cantoni G. L., Activation of methionine for transmethylation. III. The methionine-activating enzyme of Bakers' yeast. The Journal of Biological Chemistry 1958 231 1 481 492 2-s2.0-0000282525
166. Mato J. M., Alvarez L., Ortiz P., Pajares M. A., S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacology and Therapeutics 1997 73 3 265 280 2-s2.0-0030920140 10.1016/S0163-7258(96)00197-0
167. Jia W., Li H., He Y.-W., The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood 2005 106 12 3854 3859 2-s2.0-28444446705 10.1182/blood-2005-04-1658
168. Baxter J. D., Webb P., Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Reviews Drug Discovery 2009 8 4 308 320 2-s2.0-64049099095 10.1038/nrd2830
169. Baxter J. D., Dillmann W. H., West B. L., Huber R., Furlow J. D., Fletterick R. J., Webb P., Apriletti J. W., Scanlan T. S., Selective modulation of thyroid hormone receptor action. Journal of Steroid Biochemistry and Molecular Biology 2001 76 1-5 31 42 2-s2.0-0034987037 10.1016/S0960-0760(01) 00052-8
170. Webb P., Selective activators of thyroid hormone receptors. Expert Opinion on Investigational Drugs 2004 13 5 489 500 2-s2.0-2642588897 10.1517/13543784.13.5.489
171. Moreno M., De Lange P., Lombardi A., Silvestri E., Lanni A., Goglia F., Metabolic effects of thyroid hormone derivatives. Thyroid 2008 18 2 239 253 2-s2.0-39449092245 10.1089/thy.2007.0248
172. Yoshihara H. A. I., Scanlan T. S., Selective thyroid hormone receptor modulators. Current topics in medicinal chemistry 2003 3 14 1601 1616 2-s2.0-1542678305
173. Grover G. J., Mellstrom K., Ye L., Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proceedings of the National Academy of Sciences of the United States of America 2003 100 17 10067 10072
174. Bryzgalova G., Effendic S., Khan A., Rehnmark S., Barbounis P., Boulet J., Dong G., Singh R., Shapses S., Malm J., Webb P., Baxter J. D., Grover G. J., Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141. Journal of Steroid Biochemistry and Molecular Biology 2008 111 3-5 262 267 2-s2.0-49649120105 10.1016/j.jsbmb.2008. 06.010
175. Ladenson P. W., Kristensen J. D., Ridgway E. C., Olsson A. G., Carlsson B., Klein I., Baxter J. D., Angelin B., Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. New England Journal of Medicine 2010 362 10 906 916 2-s2.0-77949349469 10.1056/NEJMoa0905633
176. Berkenstam A., Kristensen J., Mellström K., Carlsson B., Malm J., Rehnmark S., Garg N., Andersson C. M., Rudling M., Sjöberg F., Angelin B., Baxter J. D., The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proceedings of the National Academy of Sciences of the United States of America 2008 105 2 663 667 2-s2.0-38649135692 10.1073/pnas.0705286104
177. Columbano A., Ledda-Columbano G. M., Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth. Cell Death and Differentiation 2003 10 supplement 1 S19 S21 2-s2.0-0037277270 10.1038/sj.cdd.4401113
178. Preston-Martin S., Pike M. C., Ross R. K., Jones P. A., Henderson B. E., Increased cell division as a cause of human cancer. Cancer Research 1990 50 23 7415 7421 2-s2.0-0025688248
179. Farber E., Hepatocyte proliferation in stepwise development of experimental liver cell cancer. Digestive Diseases and Sciences 1991 36 7 973 978 2-s2.0-0025775739
180. Columbano A., Shinozuka H., Liver regeneration versus direct hyperplasia. The FASEB Journal 1996 10 10 1118 1128 2-s2.0-0029845271